PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

EJNMMI Research

Table 5 Univariate analysis for the association of ⁶⁸Ga-PSMA-11 PET findings with Gleason Score

	No. of patients	Odds ratio	95% CI	p value*
miTNM classification, no., n = 186
miT status
2	125	Reference
≥ 3a	61	2.696	1.39–5.23	0.003
miN status
No LN metastasis	168	Reference
With LN metastasis	18	2.187	0.812–5.887	0.122
SUV_mean of prostatic lesions	183	1.020	0.986–1.056	0.248
SUV_max of prostatic lesions	183	1.017	0.995–1.040	0.138
TV of prostatic lesions	183	0.981	0.941–1.022	0.353
TL of prostatic lesions	183	1.006	1–1.012	0.056

CI confidence interval, LN lymph node, PET positron emission tomography, PSMA prostate-specific membrane antigen, SUV standardized uptake value, TL total lesion, TV tumor volume
*Significant associations are given in bold